vs
弗雷斯特研究公司（FORR）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
弗雷斯特研究公司的季度营收约是RIGEL PHARMACEUTICALS INC的1.4倍（$101.1M vs $69.8M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs -33.5%，领先417.6%），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs -6.5%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 0.5%）
福雷斯特研究公司是一家全球领先的研究咨询机构，主营业务涵盖行业研究、管理咨询与行业峰会举办，客户群体包括全球大型企业、科技公司与消费领域领军企业，公司总部位于美国马萨诸塞州剑桥市。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
FORR vs RIGL — 直观对比
营收规模更大
FORR
是对方的1.4倍
$69.8M
营收增速更快
RIGL
高出27.7%
-6.5%
净利率更高
RIGL
高出417.6%
-33.5%
两年增速更快
RIGL
近两年复合增速
0.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $101.1M | $69.8M |
| 净利润 | $-33.9M | $268.1M |
| 毛利率 | 56.7% | 91.5% |
| 营业利润率 | -36.6% | 33.2% |
| 净利率 | -33.5% | 384.0% |
| 营收同比 | -6.5% | 21.2% |
| 净利润同比 | -7941.4% | 1769.2% |
| 每股收益（稀释后） | $-1.75 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FORRRIGL
| Q4 25 | $101.1M | $69.8M | ||
| Q3 25 | $94.3M | $69.5M | ||
| Q2 25 | $111.7M | $101.7M | ||
| Q1 25 | $89.9M | $53.3M | ||
| Q4 24 | $108.0M | $57.6M | ||
| Q3 24 | $102.5M | $55.3M | ||
| Q2 24 | $121.8M | $36.8M | ||
| Q1 24 | $100.1M | $29.5M |
净利润FORRRIGL
| Q4 25 | $-33.9M | $268.1M | ||
| Q3 25 | $-2.1M | $27.9M | ||
| Q2 25 | $3.9M | $59.6M | ||
| Q1 25 | $-87.3M | $11.4M | ||
| Q4 24 | $432.0K | $14.3M | ||
| Q3 24 | $-5.8M | $12.4M | ||
| Q2 24 | $6.3M | $-1.0M | ||
| Q1 24 | $-6.7M | $-8.2M |
毛利率FORRRIGL
| Q4 25 | 56.7% | 91.5% | ||
| Q3 25 | 60.0% | 93.2% | ||
| Q2 25 | 55.5% | 95.6% | ||
| Q1 25 | 55.9% | 91.7% | ||
| Q4 24 | 58.8% | 89.9% | ||
| Q3 24 | 60.5% | 85.5% | ||
| Q2 24 | 57.3% | 92.4% | ||
| Q1 24 | 54.9% | 93.1% |
营业利润率FORRRIGL
| Q4 25 | -36.6% | 33.2% | ||
| Q3 25 | 4.7% | 40.9% | ||
| Q2 25 | 6.2% | 60.1% | ||
| Q1 25 | -97.5% | 23.9% | ||
| Q4 24 | -0.5% | 28.9% | ||
| Q3 24 | -0.7% | 25.4% | ||
| Q2 24 | 9.3% | 1.2% | ||
| Q1 24 | -9.3% | -23.6% |
净利率FORRRIGL
| Q4 25 | -33.5% | 384.0% | ||
| Q3 25 | -2.3% | 40.2% | ||
| Q2 25 | 3.5% | 58.6% | ||
| Q1 25 | -97.1% | 21.5% | ||
| Q4 24 | 0.4% | 24.9% | ||
| Q3 24 | -5.7% | 22.5% | ||
| Q2 24 | 5.2% | -2.8% | ||
| Q1 24 | -6.7% | -27.9% |
每股收益（稀释后）FORRRIGL
| Q4 25 | $-1.75 | $14.11 | ||
| Q3 25 | $-0.11 | $1.46 | ||
| Q2 25 | $0.20 | $3.28 | ||
| Q1 25 | $-4.62 | $0.63 | ||
| Q4 24 | $0.02 | $0.82 | ||
| Q3 24 | $-0.30 | $0.70 | ||
| Q2 24 | $0.33 | $-0.06 | ||
| Q1 24 | $-0.35 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $63.3M | $155.0M |
| 总债务越低越好 | — | $52.5M |
| 股东权益账面价值 | $126.5M | $391.5M |
| 总资产 | $404.0M | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资FORRRIGL
| Q4 25 | $63.3M | $155.0M | ||
| Q3 25 | $65.1M | $137.1M | ||
| Q2 25 | $67.8M | $108.4M | ||
| Q1 25 | $75.6M | $77.1M | ||
| Q4 24 | $56.1M | $77.3M | ||
| Q3 24 | $62.8M | $61.1M | ||
| Q2 24 | $58.9M | $49.1M | ||
| Q1 24 | $61.4M | $49.5M |
总债务FORRRIGL
| Q4 25 | — | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | — | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M | ||
| Q1 24 | — | $60.0M |
股东权益FORRRIGL
| Q4 25 | $126.5M | $391.5M | ||
| Q3 25 | $157.7M | $117.6M | ||
| Q2 25 | $159.5M | $81.9M | ||
| Q1 25 | $147.4M | $18.6M | ||
| Q4 24 | $229.5M | $3.3M | ||
| Q3 24 | $234.3M | $-14.6M | ||
| Q2 24 | $237.1M | $-29.9M | ||
| Q1 24 | $230.9M | $-31.7M |
总资产FORRRIGL
| Q4 25 | $404.0M | $513.6M | ||
| Q3 25 | $414.2M | $242.5M | ||
| Q2 25 | $436.0M | $206.7M | ||
| Q1 25 | $439.8M | $176.0M | ||
| Q4 24 | $503.9M | $164.0M | ||
| Q3 24 | $505.3M | $139.4M | ||
| Q2 24 | $524.2M | $128.4M | ||
| Q1 24 | $555.7M | $126.5M |
负债/权益比FORRRIGL
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-3.2M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | $-4.3M | — |
| 自由现金流率自由现金流/营收 | -4.2% | — |
| 资本支出强度资本支出/营收 | 1.1% | — |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | $18.1M | — |
8季度趋势，按日历期对齐
经营现金流FORRRIGL
| Q4 25 | $-3.2M | $22.0M | ||
| Q3 25 | $1.2M | $24.0M | ||
| Q2 25 | $-3.6M | $30.5M | ||
| Q1 25 | $26.7M | $-893.0K | ||
| Q4 24 | $-1.8M | $14.5M | ||
| Q3 24 | $264.0K | $21.7M | ||
| Q2 24 | $-2.9M | $302.0K | ||
| Q1 24 | $611.0K | $-5.0M |
自由现金流FORRRIGL
| Q4 25 | $-4.3M | — | ||
| Q3 25 | $524.0K | — | ||
| Q2 25 | $-4.2M | — | ||
| Q1 25 | $26.1M | — | ||
| Q4 24 | $-2.5M | — | ||
| Q3 24 | $-223.0K | — | ||
| Q2 24 | $-3.7M | — | ||
| Q1 24 | $-815.0K | — |
自由现金流率FORRRIGL
| Q4 25 | -4.2% | — | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | -3.8% | — | ||
| Q1 25 | 29.0% | — | ||
| Q4 24 | -2.3% | — | ||
| Q3 24 | -0.2% | — | ||
| Q2 24 | -3.1% | — | ||
| Q1 24 | -0.8% | — |
资本支出强度FORRRIGL
| Q4 25 | 1.1% | — | ||
| Q3 25 | 0.7% | — | ||
| Q2 25 | 0.5% | — | ||
| Q1 25 | 0.7% | — | ||
| Q4 24 | 0.6% | — | ||
| Q3 24 | 0.5% | — | ||
| Q2 24 | 0.7% | — | ||
| Q1 24 | 1.4% | — |
现金转化率FORRRIGL
| Q4 25 | — | 0.08× | ||
| Q3 25 | — | 0.86× | ||
| Q2 25 | -0.93× | 0.51× | ||
| Q1 25 | — | -0.08× | ||
| Q4 24 | -4.24× | 1.01× | ||
| Q3 24 | — | 1.75× | ||
| Q2 24 | -0.46× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FORR
| Research Segment | $82.2M | 81% |
| Consulting Segment | $16.2M | 16% |
| Billable Expenses | $1.5M | 2% |
| Professional Services | $1.4M | 1% |
RIGL
暂无分部数据
